At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 303 enrolled
Drug / intervention
mRNA-1608 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
In Brief
A Phase 2 clinical trial evaluating mRNA-1608 and BEXSERO for Genital Herpes. Completed, enrolled 303 participants across 23 sites.
Detailed Summary
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Herpes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartSep 2023
First PostedSep 2023
Primary CompletionApr 2025
TodayJul 2026
First PostedSep 13, 2023
Enrollment StartSep 6, 2023
Primary CompletionApr 25, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.8 years ago
Interventions
mRNA-1608biological
Sterile liquid for injection
BEXSERObiological
A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.